-
Neurotrope Alzheimer's Candidate Could Generate Revenue Beginning In 2024, Analyst Says
Friday, March 9, 2018 - 11:21am | 362Read More...Alzheimer's drug research has a high failure rate, and symptoms of the disease start appearing long after amyloid plaques — which are responsible for interruption of cell-to-cell signal transfer — deposit on the brain. The Analyst Roth Capital Partners analyst Robert LeBoyer...
-
Analyst: Neurotrope's Bryostatin-1 Trial Data Justifies Additional Studies
Monday, May 1, 2017 - 10:53am | 419Read More...Shares of Neurotrope Inc (NASDAQ: NTRP), a biopharmaceutical company focused on developing a therapy called bryostatin-1 for the treatment of Alzheimer's disease, lost more than half of its value on Monday after a planned release of clinical data failed to impress investors. Investors On A...
-
Aegis Ponders Neurotrope's Odds Of Pulling The 'Alzheimer's Sword From The Stone'
Wednesday, April 12, 2017 - 9:47am | 410Read More...Neurotrope Inc (NASDAQ: NTRP) is in the process of developing Bryostatin-1 “as a stimulator of PKCε, an early regulator of brain cell growth and repair. A Phase IIb trial has completed enrollment in Alzheimer’s disease, with data expected in late April 2017,” Aegis Capital...
-
Why Aegis Capital Loves Adamas...And How To Bet On Parkinson's Treatment
Tuesday, September 22, 2015 - 11:17am | 300Read More...The share price of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) has risen a little over 13 percent year-to-date. Aegis Capital’s Robert LeBoyer has initiated coverage of Adamas Pharmaceuticals with a price target of $29. LeBoyer expects the stock to be driven by the Phase III data...
